Effect of Combination Therapy with Extended-Release Metformine and Glimepiride on Carbohydrate and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus

Abstract

The aim of investigation — to study the efficiency and safety of the therapy with extended-release metformine combined with glimepiride in patients with type 2 diabetes mellitus (DM). Materials and methods. There were 35 patients with type 2 DM under a supervision. Before inclusion in the study, patients received metformine without the achievement of target glycemic levels, and from the moment of supervision a combined hypoglycemic therapy with glimepirtide and extended-release metformine (Duglimax, manufactured by Kusum Pharm, Ukraine) was additionally administered in combination with metformine (Metamine SR, manufactured by Kusum Pharm, Ukraine). The treatment duration was 12 weeks. The indices of carbohydrate, lipid metabolism, the degree of insulin resistance and body weight were evaluated before and after the treatment. Results. As a result of the research, the positive effect of the combined therapy with glimepiride and metformine on the carbohydrate and lipid metabolism and, in total, on the risk factors of cardiovascular complications (dislipidemia, insulin resistance, hyperinsulinemia) has been established. The level of glycated hemoglobin compared with baseline values has reduced by 1.5 % (p 0.05). Changes of anthropometric parameters (body mass index, waist and hip circumference) were not statistically significant (p > 0.05). Against the background of combined treatment, there were not registered hypoglycemic reactions and side effects. Conclusions. Combination hypoglycemic therapy with extended-release metformin and glimepiride during 12 weeks resulted in a statistically significant improvement of carbohydrate and lipid metabolism.

Keywords

• type 2 diabetes mellitus
• metformine
• glimepiride